Study of IparomlimabTuvonralimab Combined With Nab-paclitaxel and Cisplatin Before Surgery for Locally Advanced Cervical Cancer
Led by Xijing Hospital · Updated on 2026-10-15
34
Participants Needed
1
Research Sites
48 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to find out if a combination of IparomlimabTuvonralimab with nab-paclitaxel and cisplatin can treat locally advanced cervical cancer in adult female patients. It focuses on assessing the pathological complete response rate after this neoadjuvant treatment and also monitors objective response rate, progression-free survival, overall survival, and changes in tumor immune environment and biomarkers. This is a single-arm trial without a comparison group.
Participants receive three cycles of intravenous IparomlimabTuvonralimab at 5 mgkg, nab-paclitaxel at 260 mgm2, and cisplatin at 75 mgm2 every three weeks. If cisplatin is not tolerated, carboplatin may be used instead. After the neoadjuvant therapy, participants undergo radical surgery. Throughout the study, scheduled imaging, blood tests, and tissue biomarker assessments are performed.
During the trial, participants will have regular follow-up visits to monitor survival and safety. Researchers evaluate the pathological complete response within two weeks after surgery and measure objective response after the three treatment cycles. They also track progression-free and overall survival for up to 36 months post-surgery, as well as treatment-related side effects and changes in immune biomarkers at baseline, before surgery, and immediately after surgery. The study lasts until June 2028.
CONDITIONS
Brief Title
Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Research Team
S
Shujuan Liu, MD
X
Xiaohui Lv, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Female patients aged between 18 and 70 years (inclusive)
Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
Previously untreated stage IB3 or IIA2 cervical cancer according to FIGO 2018
At least one measurable lesion with lymph node diameter less than 1.5 cm by MRI
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Ability to provide tumor tissue samples for PD-L1 expression testing
Laboratory values meeting specified blood count and organ function requirements
Negative pregnancy test, not breastfeeding, and commitment to use effective contraception from consent until six months after last drug dose
Voluntary participation with good compliance and ability to understand and sign informed consent
You will not qualify if you...
Presence of distant metastatic disease
Prior anti-cancer therapy including surgery (except biopsy), radiation, chemotherapy, immunotherapy, or targeted treatments
Previous treatment with immune checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 antibodies
Active malignancy within three years except localized curable tumors or the cervical cancer under study
Active autoimmune disease or history requiring systemic treatment within two years, except well-controlled specific conditions
Primary immunodeficiency or relevant medical history
Use of immunosuppressive agents within 14 days or need for daily systemic corticosteroids above specified doses
Positive HIV antibody or active syphilis infection
Active hepatitis B or C infection with elevated viral load
Active infection requiring intravenous antimicrobial treatment within 14 days
Active or history of tuberculosis
Severe cardiovascular disease within past six months
Uncontrolled hypertension
Interstitial lung disease or history requiring corticosteroid treatment
Clinically significant hydronephrosis not relieved by intervention
Live or attenuated vaccines within 28 days before or during study
Prior organ or stem cell transplantation
Severe allergic reactions to study drug components
Participation in other investigational drug trials within 28 days
History of neurological or psychiatric disorders, substance abuse, or drug addiction
Any condition deemed unsuitable by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 9 weeks
Participants receive three cycles of intravenous Iparomlimab/Tuvonralimab combined with nab-paclitaxel and cisplatin (or carboplatin if needed) every three weeks as neoadjuvant therapy before surgery.
3 treatment visits every 3 weeks
Surgery
Duration - Within 2 weeks following treatment
Participants undergo radical surgery to remove cervical cancer after completing neoadjuvant therapy.
1 surgical procedure visit
Follow-up
Duration - Up to 36 months
Participants are followed regularly for survival, safety assessments, and biomarker monitoring for up to 36 months after surgery.
Regular follow-up visits as scheduled
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of Nanocrystalline Megestrol Acetate with Chemoradiotherapy in Advanced Cervical Cancer
Evaluating the Patient-Tailored ARCHITECT Applicator for High-Dose-Rate Brachytherapy in Locally Advanced Cervical Cancer
Comparison of Surgery Staging Versus Image Staging for Treatment of Locally Advanced Cervical Cancer
Study of Curcumin Supplementation Effects on p53 Levels and Cell Death in Women With Advanced Cervical Cancer Receiving Chemoradiotherapy
Phase III Study Comparing Weekly Cisplatin Versus Gemcitabine with Radiation for Women 18 and Older with Locally Advanced Cervical Cancer and Kidney Function Preserved
Study of IparomlimabTuvonralimab Combined With Nab-paclitaxel and Cisplatin Before Surgery for Locally Advanced Cervical Cancer
Comprehensive Study of Tumor Environment Changes During Radiotherapy for Cervical and Pancreatic Cancer
Neoadjuvant Chemoimmunotherapy With Surgery Compared to Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in Women Ages 18 to 70
Phase 2 Study of Cadonilimab Plus Cisplatin Chemotherapy Before Surgery for Locally Advanced Cervical Cancer
Phase 2 Study of Neoadjuvant Chemotherapy Plus Camrelizumab for PD-L1-negative Locally Advanced Cervical Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari...
Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix.